Euronext Growth

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Disability, Conference, Euronext Growth, Per, Risk, Patient, Sarcopenia, Ageing, Adapted automobile, Safety, Therapy, Poster, Metre, Pharmaceutical industry

The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.

Key Points: 
  • The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.
  • Based on outcome of the SARA-INT phase 2 study and on results from the SPRINTT and LIFE studies, Biophytis designed an interventional, randomized, double-blind, placebo-controlled clinical phase 3 study (the SARA-31 study), expected to include 932 subjects.
  • The poster presented at the ICFSR conference, which details the objectives and the design of the study, can be viewed by clicking on this link .
  • Stanislas Veillet, CEO of Biophytis, stated: "The SARA-31 phase 3 study will assess the efficacy and safety of RuvembriTM in the treatment of sarcopenic patients at risk of functional decline and disability.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Metabolism, Obesity, Euronext Growth, Skeletal muscle, Patient, Nature Biotechnology, Weight loss, Trial of the century, OBA, Facial muscles, Sarcopenia, Therapy, MAS, Pharmaceutical industry

These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.

Key Points: 
  • These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.
  • We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
  • The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024.
  • Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Euronext Growth, Mass meeting, Meeting, Therapy

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Key Points: 
  • RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
    RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
    Paris (France) and Cambridge (Massachusetts, USA), April 04, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
  • Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 30% of the shareholders present or represented.
  • The resolutions, which notably included a renewal of the usual financial delegations granted to the Company, were all approved.
  • The results of the votes are available on the Biophytis website in the "Investors / General Meetings" section.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Euronext Growth, Gene, DNA, HSPC, Society, Therapy, Cell, Gene editing, Vaccine

Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).

Key Points: 
  • Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).
  • Gene therapy using hematopoietic and progenitor stem cells (HSPC) has the potential to provide a lifelong supply of genetically encoded therapeutics.
  • Gene editing strategies enabling supra-endogenous expression of therapeutics often rely on constitutive promoters resulting in transgene overexpression irrespective of cellular differentiation, which could be detrimental for HSPC function.
  • Full abstracts and presentations will be available on Cellectis’ website following the event:

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Sostravel.com Approves the Annual Financial Statement Draft as of December 31, 2023: Profit of €1.169 Million and Gross Booking Value Growth of 29.6%

Retrieved on: 
Tuesday, April 2, 2024
Other Travel, Lodging, Destinations, Travel, Other Transport, Vacation, Air, Transport, The Company, Plan, Growth, Euronext Growth, SOS, Private label

Sostravel.com S.p.A. (Euronext Growth Milan: SOS and OTCQB New York: SOSAF), an Italian digital travel platform for bookings, itineraries, flight and airport information, car rental, experiences, and travel tech services including Lost Luggage Concierge and Dr. Travel, through the apps sostravel and flio as well as the platforms www.sostravel.com and www.amareitalia.com , ("SosTravel" or the "Company"), announces that the Board of Directors, meeting today, has approved the annual financial statement as of December 31, 2023.

Key Points: 
  • Sostravel.com S.p.A. (Euronext Growth Milan: SOS and OTCQB New York: SOSAF), an Italian digital travel platform for bookings, itineraries, flight and airport information, car rental, experiences, and travel tech services including Lost Luggage Concierge and Dr. Travel, through the apps sostravel and flio as well as the platforms www.sostravel.com and www.amareitalia.com , ("SosTravel" or the "Company"), announces that the Board of Directors, meeting today, has approved the annual financial statement as of December 31, 2023.
  • Carmine Colella, CEO of Sostravel.com, commented: "The Gross Booking Value results as of March 27, 2024, amounting to 7.17 million Euros (an increase of 29.6%), and the services of the 'Passenger Services' business unit, which includes Lost Luggage Concierge and Dr. Travel, showing strong growth for the period, are the outcome of the performance of the dedicated team that we deployed in the fourth quarter of 2023, and the great success of the Private Label products in Sardinia and Kenya, which enable us to confirm the objectives of the Industrial Plan for 2027."
  • The Company has exceeded the EBITDA targets presented in the original version of the Plan published in February 2023.
  • The Company therefore confirms the objectives of the Industrial Plan for 2027, as summarized below:

Tilak Healthcare Strengthens Its Leadership Team

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Human Resources, Optical, Finance, Health, Health Technology, Professional Services, Other Health, Retina, Social Security, Conditional sentence, HEC Paris, Euronext Growth, CFO, Partnership, Knowledge, Health care, Information, University, Prescription, Head, Visual impairment, Laboratory, ParisTech, Drug, Alcon, Social, Genomics, Pharmacy, Directorate, Multimedia, Ministry, Doctorate

Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).

Key Points: 
  • Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).
  • For Benoît Gueugnon, CFO: "I would like to thank the management team as well as the investors of Tilak Healthcare (iBionext, Elaia, Swen Capital, Matmut, Caphorn, and Laboratoires Théa).
  • For Dr. Patricia Zilliox: "I am impressed by Tilak Healthcare's journey, establishing itself as a leader in digital health in ophthalmology.
  • Undoubtedly, these achievements and the quality of the team are undeniable assets for approaching the American market."

Coty Wins this year’s Euronext Best listing Award in the Large Cap category

Retrieved on: 
Tuesday, March 19, 2024
Finance, Luxury, Cosmetics, Retail, Professional Services, Capital, Conference, Growth, Euronext Growth, Best, Trust, Beauty, Skin, Euronext Paris, COTY, Security (finance)

Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, has won this year’s Euronext Best Listing Award in the Large Cap category, at the 12th edition of the Euronext Annual Conference held on March 19, 2024 in Paris.

Key Points: 
  • Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, has won this year’s Euronext Best Listing Award in the Large Cap category, at the 12th edition of the Euronext Annual Conference held on March 19, 2024 in Paris.
  • The award recognizes the success of Coty's global offering, the largest to date on Euronext Growth®.
  • The secondary listing on Euronext Paris was a resounding success for the company, raising €339.2 million, making it the 47th listing on Euronext in 2023 and the 11th international listing.
  • Sue Nabi, CEO of Coty, said: "We are immensely proud to receive this award for the Best Listing Award of the year in the Large Cap category, at the Euronext Stock Market Awards.